Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FOXK2 amplification promotes breast cancer development and chemoresistance

18 Jun 2024

Abstract excerpt

Oncogene activation through DNA amplification or overexpression is a crucial driver of cancer initiation and progression. The FOXK2 gene, located on chromosome 17q25, encodes a transcription factor with a forkhead DNA-binding domain. Analysis of genomic datasets reveals that FOXK2 is frequently amplified and overexpressed in breast cancer, correlating with poor patient survival. Knockdown of FOXK2 significantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to FOXO transcription factor regulation
Share to Genomics, phytochemicals, and oxidative stress

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38901667
DOI: 10.1016/j.canlet.2024.217074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FOXK2 amplification promotes breast cancer development and chemoresistancePMID 38901667Read ↗

<i>FOXK2</i> amplification and overexpression promotes breast cancer development and chemoresistanceSemantic proximity Read ↗

FOXK2 Transcription Factor and Its Emerging Roles in CancerSemantic proximity Read ↗

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.Semantic proximity Read ↗

Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistanceSemantic proximity Read ↗

CDKL2 promotes epithelial-mesenchymal transition and breast cancer progressionSemantic proximity Read ↗

FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cellsSemantic proximity Read ↗

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT InhibitionSemantic proximity Read ↗

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read ↗

IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.Semantic proximity Read ↗

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read ↗

Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancerSemantic proximity Read ↗

Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.